Autifony Therapeutics is dedicated to developing new drugs to treat rare CNS disorders using pioneering science
“Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery.
Autifony is using its pioneering expertise in ion channels to develop novel treatments for serious rare and genetic disorders of the central nervous system, such as Fragile X, Progressive Myoclonic Epilepsy and Amyotrophic Lateral Sclerosis, as well as other more common and devastating neuropsychiatric disorders, including Schizophrenia and Bipolar Disorder.
The company is also one of the leaders in pharmaceutical approaches to the treatment of hearing disorders. Hearing disorders affect a significant proportion of the population, and while devices such as hearing aids and cochlear implants can ease the problems for some, many people suffer silently. As well as causing social isolation and distress, hearing loss also brings with it a considerable economic cost to society, with increased risk of unemployment, the need for carer support, and other costs.”